<DOC>
	<DOCNO>NCT00521274</DOCNO>
	<brief_summary>The purpose study evaluate role combination therapy Trovax plus Docetaxel Docetaxel alone patient prostate cancer rise prostate specific antigen ( PSA ) .</brief_summary>
	<brief_title>Study Trovax® Plus Docetaxel Versus Docetaxel Alone Patients With Progressive Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>Docetaxel active chemotherapeutic agent treatment prostate cancer . Trovax vaccine target 5T4 receptor tumor cell . 5T4 detected majority primary prostate cancer . Based pre-clinical clinical data , may advantageous administer cancer vaccine chemotherapy enhance immune response , thus lead therapeutic approach patient metastatic androgen independent prostate cancer ( AIPC ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate . Progressive disease androgen deprivation . ECOG Status &lt; 2 . No prior chemotherapy prostate cancer therapy At least four week lapse since prior chemotherapy ( administer ) Patients stable dos bisphosphonates show subsequent tumor progression may continue medication ; however , patient allow initiate bisphosphonate therapy within one month prior start therapy throughout study . Clinically immunocompetent . Free clinically apparent/active autoimmune disease Absolute Lymphocyte Count ≥ 500/µl , ANC &gt; 1200/µl , Platelet count &gt; 100,000/µl , Hemoglobin &gt; 10 mg/dl , Peripheral neuropathy &lt; 1 . No evidence active ischemia ECG Age great 18 year Patients receive prior chemotherapy . Patients receive hormonal therapy , include dose megestrolacetate ( Megace ) , Proscar ( finasteride ) , herbal product know decrease PSA level ( e.g. , Saw Palmetto PCSPES ) , systemic corticosteroid must discontinue agent least 4 week prior enrollment . Progressive disease ( define ) must document discontinuation hormonal therapy . Patients initiate bisphosphonate therapy within one month prior start therapy throughout study . No supplement complementary medicines/botanicals permit study , except combination follow : conventional multivitamin supplement , selenium , lycopene , soy supplement , Vitamin E Patients review label doctor prior enrollment , discontinue disallow agent prior study enrollment Major surgery radiation therapy complete &lt; 4 week prior enrollment . Prior radiopharmaceutical ( strontium , samarium ) within 8 week prior enrollment . `` Currently active '' second malignancy , nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy 5 year previously know evidence residual recurrent disease Serious intercurrent infection nonmalignant medical illness uncontrolled . Psychiatric illnesses/social situation would limit compliance protocol requirement . AST ALT Alkaline Phosphatase must within range allow eligibility . In determine eligibility abnormal two value ( AST ALT ) use . The bilirubin must within normal limit . Renal function creatinine ≥1.5 x ULN . Known allergy egg protein . Known allergy neomycin . History allergic response previous vaccinia vaccination . Chronic oral corticosteroid use ( especially antiemetic ) unless prescribe replacement therapy case adrenal insufficiency . Known test positive HIV hepatitis B C test prior study require . Clinical indication reduce cardiac function ejection fraction ≤ 40 % . Requirement radiotherapy ( sign disease progression class withdrawal criterion ) . Concurrent chemotherapy , immunotherapy radiation therapy No investigational commercial agent therapy include protocol treatment may administer intent treat patient 's malignancy . Prior exposure TroVax® .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Progressive Hormone Refractory Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>MVA 5T4</keyword>
	<keyword>Trovax®</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>M3thodist</keyword>
</DOC>